ACTIVE-A: Cardiovascular End Points by Treatment Group
End point | Clopidogrel, n (%/y) | Placebo, n (%/y) | Relative risk (95% CI) | p |
---|---|---|---|---|
Major vascular events | 832 (6.8) | 924 (7.6) | 0.89 (0.81-0.98) | .01 |
Stroke | 296 (2.4) | 408 (3.3) | 0.72 (0.62-0.83) | <.001 |
MI | 90 (0.7) | 115 (0.9) | 0.78 (0.59-1.03) | .08 |
Strokes of ischemic or unknown origin were reduced significantly, and hemorrhagic stroke was increased, although not significantly.